Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
Public ClinicalTrials.gov record NCT01150890. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Study identification
- NCT ID
- NCT01150890
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- Brodalumab Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 8, 2010
- Primary completion
- Oct 14, 2011
- Completion
- Oct 14, 2011
- Last update posted
- Jan 2, 2022
2010 – 2011
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Dothan | Alabama | — | — |
| Research Site | Lowell | Arkansas | — | — |
| Research Site | Jacksonville | Florida | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | Hammond | Louisiana | — | — |
| Research Site | Chevy Chase | Maryland | — | — |
| Research Site | Rochester | Minnesota | — | — |
| Research Site | Mexico | Missouri | — | — |
| Research Site | Egg Harbor | New Jersey | — | — |
| Research Site | Great Neck | New York | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Wilmington | North Carolina | — | — |
| Research Site | Germantown | Tennessee | — | — |
| Research Site | Nashville | Tennessee | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Logan | Utah | — | — |
| Research Site | Ogden | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01150890, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 2, 2022 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01150890 live on ClinicalTrials.gov.